(79 days)
This in vitro diagnostic method is intended to quantitatively measure ferritin (an iron-storage protein) in human serum on the Bayer Immuno 1 System. Measurements of ferritin aid in the diagnosis of diseases affecting iron metabolism, such as hemochromatosis (iron overload) and iron deficiency anemia.
This diagnostic method is not intended for use on any other system.
The Bayer Immuno 1 Ferritin (FER) Method uses a homogenous sandwich immunoassay format. Samples are reacted with Ferritin Antibody Conjugate R1 (Antibody linked to FITC) and Ferritin Antibody Conjugate R2 (Antibody linked to calf intestine alkaline phosphatase) and incubated on the Immuno 1 system at 37°C. The anti-Ferritin antibody conjugates combine with sample ferritin to form a sandwich complex, followed by addition of monoclonal Immuno-Magnetic particle (mIMP) Reagent binds the antibody which After further incubacomplexes. tion, the mIMP/antibody complex is washed and a para-nitrophenyl phosphate substrate, which reacts with the enzyme conjugate, is added. The resulting paranitrophenoxide is monitored at 405 nm and 450 nm using a filter switch protocol. The dose/ response curve is proportional to the amount of ferritin in the sample.
This document describes the validation of a change to the Bayer Immuno 1™ System Ferritin Assay, specifically an increase in the concentration of the Level 6 calibrator from 1000 ng/mL to 2500 ng/mL. The primary goal of the study was to demonstrate that this change does not negatively impact the assay's performance and that the new assay performance is equivalent to previously demonstrated performance.
1. Acceptance Criteria and Reported Device Performance
The document implies that the acceptance criteria for the new assay performance are met if key performance characteristics like precision, analytical sensitivity, and correlation with the existing method remain comparable or within acceptable ranges. The specific acceptance criteria themselves are not explicitly listed in a single table, but rather embedded within the description of each study.
| Performance Metric | Acceptance Criteria (Implied/Existing) | Reported Device Performance (with L6=2500 ng/mL) |
|---|---|---|
| Imprecision | No change from existing method sheet imprecision estimates. NCCLS document EP5-T2 guidelines followed. | Proposed L6 Calibrator @ 2500 ng/mL:Pooled Human Serum (Pool-1): Mean=25.2, Within SD=0.5, Within %CV=1.9, Total SD=0.6, Total %CV=2.6Bayer TESTpoint Controls (Control 1): Mean=28.8, Within SD=0.5, Within %CV=1.8, Total SD=0.6, Total %CV=2.2Bayer TESTpoint Controls (Control 2): Mean=104.6, Within SD=0.5, Within %CV=0.5, Total SD=1.4, Total %CV=1.3Pooled Human Serum (Pool-2): Mean=206.7, Within SD=8.6, Within %CV=4.1, Total SD=8.6, Total %CV=4.1Bayer TESTpoint Controls (Control 3): Mean=237.4, Within SD=6.0, Within %CV=2.5, Total SD=6.0, Total %CV=2.5Current Method Sheet (for comparison):Control 1: Mean=21.1, Within SD=0.2, Within %CV=1.0, Total SD=1.5, Total %CV=7.1Control 2: Mean=148.1, Within SD=3.2, Within %CV=2.1, Total SD=7.4, Total %CV=5.0Control 3: Mean=344.2, Within SD=8.5, Within %CV=2.5, Total SD=17.1, Total %CV=5.0Conclusion: "The proposed new Level 6 calibrator does not impact imprecision estimates: no change will be made to the method sheet." The reported numbers appear comparable, and in some cases, the %CVs for the proposed L6 are lower than the current method, supporting the claim of no impact. |
| Analytical Sensitivity | Unchanged from current expected value (0.3 ng/mL). | "This value was determined to be 0.3 ng/mL, unchanged from our current expected value." |
| Correlation (Samples < 1000 ng/mL) | Excellent correlation, to be added to existing comparisons. | y = 1.049x - 2.577, r = 0.999, Sy.x = 6.94, n = 72. Range: 30.2 - 966.7. ("All samples assayed 'neat'"). |
| Correlation (Samples > 1000 ng/mL) | Good correlation with diluted current method samples considered. | y = 0.975x + 291.1, r = 0.931, Sy.x = 162.2, n = 30. Range: 812 - 2412. (Current samples were diluted 1:5). |
| Correlation (All Samples Combined) | Good overall correlation. | y = 1.162x - 9.21, r = 0.990, Sy.x = 101.7, n = 102. Range: 30.2 - 2412. (Includes neat and diluted samples). |
| Dilution of Over-Range Samples | No statistical difference between recoveries, regression analysis r ≥ 0.975, slope ≥ 0.975. | T-test: t Stat = -1.725 (less than t Critical one-tail 2.015 and two-tail 2.571), meaning no statistical difference. Regression analysis: y = 0.991x + 185.7, r = 0.998, Sy.x = 201.9, n = 6. All samples were diluted 1:10. |
| Specificity/Cross-Reactivity | No impact / "No change will be made to the method sheet." | "No reformulations were made to Reagents and the proposed new Level 6 calibrator will not impact specificity." "No reformulations were made to Reagents and the proposed new Level 6 calibrator will not impact cross-reactivity." (No specific new data presented due to no change in reagents). |
| Reference Intervals | No impact / "no new claim is being made." | "The change to a higher Level 6 calibrator does not impact sample recoveries, so no new claim is being made." (No specific new data presented as no impact was expected/observed). |
| Calibrator Stability | Stability must be determined and verified. | "Data for real-time stability will continue to be generated for at least two years. Additional performance testing will occur at specific time points to verify on-system stability claims for the life-time of the product." (Study is ongoing). |
2. Sample Size and Data Provenance (Test Set)
-
Imprecision Study (Test Set):
- Sample Size:
- Replicate analyses of human serum (Pools 1 & 2) and Bayer TESTpoint Ligand Controls (Controls 1 to 3).
- For the 2500 ng/mL L6 calibrator, data was generated over 5 days using four replicates per day (total 20 replicates for each sample/control).
- For the current L6 calibrator, estimates were collected over 20 days using two replicates per day (total 40 replicates for each sample/control) based on NCCLS document EP5-T2.
- Data Provenance: Not explicitly stated, but implies laboratory-generated data using human serum pools and commercial controls. Likely retrospective from an internal database for the "current" method and prospective for the "proposed" method within the company's R&D facilities.
- Sample Size:
-
Correlation Data (Test Set):
- Sample Size: 102 samples.
- 72 samples with concentrations less than 1000 ng/mL.
- 30 samples with concentrations greater than 1000 ng/mL but less than 2500 ng/mL.
- Data Provenance: "obtained from outside sources." This suggests external patient samples, potentially from a variety of sources but specific countries are not mentioned. The data is retrospective in the sense that these were pre-existing samples used for comparison.
- Sample Size: 102 samples.
-
Dilution of Over-Range Samples (Test Set):
- Sample Size: 6 samples with concentrations greater than 2500 ng/mL.
- Data Provenance: Not explicitly stated, but these were "patient samples." Likely laboratory-generated from clinical samples.
3. Number of Experts and Qualifications (Ground Truth for Test Set)
This document describes the validation of an in vitro diagnostic (IVD) assay. The concept of "experts" to establish ground truth as typically understood in AI/imaging studies (e.g., radiologists interpreting images) does not directly apply here. For IVDs, the "ground truth" is typically established by:
- Reference Methods: Comparisons to established, validated methods or reference materials.
- Certified Reference Materials/Standards: Calibrators are linked to international standards (e.g., WHO 1st International Standard (IS 80/602) for Ferritin).
- Laboratory Procedures: Rigorous, standardized laboratory procedures and quality control.
In this context, the "experts" are the biomedical scientists and engineers at Bayer who designed, developed, and validated the assay, and who interpret the analytical performance data against regulatory and scientific standards (e.g., NCCLS guidelines). No specific number or qualifications of "experts" for ground truth establishment on the test set samples are given, as the "ground truth" is derived from the established analytical validity of the reference methods (the current assay) and the quantitative results themselves.
4. Adjudication Method (Test Set)
Not applicable in the context of an IVD assay validation as described. Adjudication methods (like 2+1 reader consensus) are typically used for subjective interpretations by human readers, often in medical imaging or pathology. For quantitative assays like this, performance is measured against numerical values and statistical comparisons, not expert consensus on individual sample interpretations.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study
Not applicable. This is an validation study for an in vitro diagnostic assay, not a study involving human readers interpreting cases with and without AI assistance.
6. Standalone Performance (Algorithm Only without Human-in-the-Loop)
Yes, the studies described are standalone performance evaluations of the assay system itself. The system measures ferritin levels, and its performance (imprecision, sensitivity, correlation, dilution linearity) is assessed based on its quantitative output. There is no "human-in-the-loop" component in the direct measurement of ferritin by the Immuno 1 system; the human element is in operating the instrument, performing quality control, and interpreting the numerical results.
7. Type of Ground Truth Used
- Reference Standard / Certified Material: The calibrators are standardized to the "World Health Organization (WHO) 1st International Standard (IS 80/602)." This is the ultimate ground truth for concentration assignment.
- Comparative Method: For correlation studies, the "current Bayer Immuno 1 Ferritin Assay (L6 = 1000 ng/mL)" served as the comparator or de facto "ground truth" against which the proposed assay (with L6 = 2500 ng/mL) was evaluated.
- Known Concentrations: For imprecision, analytical sensitivity, and dilution studies, laboratory-prepared human serum pools and commercial controls with their expected or established concentrations are used as the reference points.
8. Sample Size for the Training Set
The document does not explicitly delineate a "training set" in the context of machine learning. For an IVD assay, the equivalent of a "training set" would be the data used during the initial development and optimization of the assay reagents, instrument parameters, and calibration curve generation procedures.
The section "4.0 CALIBRATORS OVERVIEW" mentions: "Each production lot of calibrators is anchored against a Master Lot and value assigned by comparative analysis of twenty "new" calibrator replicates nested within twenty "master" calibrator replicates." This process of generating master lots and assigning values could be considered analogous to "training" the system's calibration.
However, a specific "training set" sample size for developing the entire assay, beyond this calibrator assignment process, is not given.
9. How the Ground Truth for the Training Set was Established
As noted in point 8, the assay development process does not typically involve a separate "training set" with distinct "ground truth" establishment as in machine learning. However, for the crucial aspect of calibration:
- International Standard Linkage: "Bayer SETpoint Ferritin Calibrators were first standardized to the World Health Organization (WHO) 1st International Standard (IS 80/602) and the linkage has been perpetuated by nested testing matches of subsequent master lots." This WHO standard forms the primary ground truth for ferritin concentration.
- Master Lot Anchoring: "Each production lot of calibrators is anchored against a Master Lot and value assigned by comparative analysis of twenty "new" calibrator replicates nested within twenty "master" calibrator replicates." This indicates a hierarchical system where new calibrator lots are assigned values relative to established master lots, which themselves trace back to the international standard.
- Control and Serum Pool Verification: "A calibration curve is then generated with the new calibrators and acceptable control and serum pool recoveries are verified before release." This ensures that the established calibration curve provides accurate results for known controls and serum pools.
{0}------------------------------------------------
Attachment 4
OCT 22 1998
KG82714
Bayer Immuno 1 ™ System
Ferritin Assay
510(k) Method Sheet Summary
Submitted by:
D. Becker
P. Dillon M. Dombalagian J. Monticello T. Nguyen
J. Roman G. Struve R. Weiss J. Wilson
23 July, 1998
Image /page/0/Picture/11 description: The image shows the Bayer company logo. The word "Bayer" is written in a bold, sans-serif font. To the right of the word is a circle with the word "Bayer" written vertically three times. A thick black line is located underneath the company name.
{1}------------------------------------------------
TABLE OF CONTENTS
| Page | ||
|---|---|---|
| 1.0 | Overview | 3 |
| 2.0 | Introduction | 4 |
| 3.0 | Assay Description | 5 |
| 4.0 | Calibrators Overview | 5 |
| 5.0 | Stability of New 2500 ng/mL Calibrator | 6 |
| 6.0 | Imprecision | 6 |
| 7.0 | Analytical Sensitivity | 7 |
| 8.0 | Correlation Data | 7 |
| 9.0 | SpecificityCross-Reactivity | 8 |
| 10.0 | Dilution of Over-Range Samples | 9 |
| 11.0 | Determination of Reference Intervals | 9 |
.
.
{2}------------------------------------------------
1.0 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
The Bayer Immuno 1 Ferritin Assay originally received 510(k) clearance when the system was first released in 1990. In response to customer inquiries, we are proposing an increase in the concentration of the Level 6 calibrator from 1000 ng/mL to 2500 ng/mL.
This change will prevent unnecessary dilution of high concentration samples required by many customers using this assay while monitoring renal dialysis patients, where the Ferritin levels often exceed 1000 ng/mL.
We propose only two changes to the Method Sheet: Communication of the new calibrator levels and a correlation showing sample recoveries are unchanged between the L6 at 1000 ng/mL and the L6 at 2500 ng/mL. This report summarizes R&D data generated to show that new assay performance is equivalent to previously demonstrated performance.
There is no proposed change to reagents - neither in their manufacture nor formulation.
| ng/mL | ||
|---|---|---|
| Calibrator | Current | Proposed |
| L1 | 0.0 | 0.0 |
| L2 | 10.0 | 10.0 |
| L3 | 40.0 | 40.0 |
| L4 | 100.0 | 100.0 |
| L5 | 500.0 | 1000.0 |
| L6 | 1000.0 | 2500.0 |
Table 1. Bayer Immuno 1 Ferritin Assay: Current and Proposed Calibrators
{3}------------------------------------------------
2.0 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Ferritin is an iron-containing protein predominantly found in the cytoplasm of hepatic and reticulo-endothelial cells. It is the primary storage compound from which iron is mobilized to the transferrin-bound serum pool and thus transferred to red blood cells for use in required body functions. In addition to intracellular ferritin, small but clinically significant amounts are found in circulating serum. The measurement of ferritin in serum is believed to reflect total iron stores of the body.
For this reason, it is important to be able to test ferritin levels from extremely low concentrations to very high concentrations.
Certain disease states are known to elevate serum ferritin concentrations independently of the patient's iron stores. These include hepatic diseases such as cirrhosis, drug or viralinduced necrosis, hepatitis, obstructive jaundice, primary hepatoma and metastatic cancer of the liver. Recently, customers have requested the ability to assay higher concentrations of ferritin without having to dilute patient samples. The Bayer Immuno 1 Ferritin Method in its current formulation allowed for a 2.5 fold increase in sample concentrations to be assaved by adding a new calibrator at 2500 ng/mL.
This change requires no change in formulation of assay reagents. A new Level 6 calibrator at 2500 ng/mL is produced and a previous L5 Calibrator at 500 ng/mL is deleted and replaced with the previous L6 of 1000 ng/mL.
{4}------------------------------------------------
The Bayer Immuno 1 Ferritin (FER) Method uses a homogenous sandwich immunoassay format. Samples are reacted with Ferritin Antibody Conjugate R1 (Antibody linked to FITC) and Ferritin Antibody Conjugate R2 (Antibody linked to calf intestine alkaline
phosphatase) and incubated on the Immuno 1 system at 37°C. The anti-Ferritin antibody conjugates combine with sample ferritin to form a sandwich complex, followed by addition of monoclonal Immuno-Magnetic particle (mIMP) Reagent binds the antibody which After further incubacomplexes. tion, the mIMP/antibody complex is washed and a para-nitrophenyl phosphate substrate, which reacts with the enzyme conjugate, is added. The resulting paranitrophenoxide is monitored at 405 nm and 450 nm using a filter switch protocol. The dose/ response curve is proportional to the amount of ferritin in the sample.
Image /page/4/Figure/3 description: The image is a graph titled "Figure 1. Proposed New Calibration Curve for Bayer Immuno 1 Ferritin Assay." The graph shows concentration in ng/mL on the x-axis and rates in mA/min on the y-axis. The graph shows a curve that increases from approximately (0,0) to (2500, 5000). The text in the image notes that the calibrator at 500 ng/mL was not used to generate this curve and is shown only as a reference to the existing curve.
. . . . . . . . . . . . . . . . CALIBRATORS OVERVIEW 4.0 .....
Bayer SETpoint Ferritin Calibrators were first standardized to the World Health Organization (WHO) 1st International Standard (IS 80/602) and the linkage has been perpetuated by nested testing matches of subsequent master lots. Each production lot of calibrators is anchored against a Master Lot and value assigned by comparative analysis of twenty "new" calibrator replicates nested within twenty "master" calibrator replicates. A calibration curve is then generated with the new calibrators and acceptable control and serum pool recoveries are verified before release. Nominal new calibrator values are: 0.0, 10.0, 40.0, 100.0, 1000.0 and 2500.0 ng/mL.
{5}------------------------------------------------
. . . . . . . . STABILITY OF NEW 2500 NG/ML CALIBRATOR 5.0 .......
Shelf life dating for the new level of Bayer Immuno 1 Ferritin Calibrator will be determined by monitoring recoveries of other calibrators, controls and serum pools under real-time and elevated temperature stressed conditions and compared to -80°C stored components. Data for real-time stability will continue to be generated for at least two years. Additional performance testing will occur at specific time points to verify on-system stability claims for the life-time of the product.
6.0. . . . ··············································································································································································
The proposed new Level 6 calibrator does not impact imprecision estimates: no change will be made to the method sheet.
Estimates of imprecision were obtained from replicate analyses of human serum (Pools 1 & 2) and Bayer TEST point Ligand Controls (Controls 1 to 3) and then compared to Method Sheet recoveries using the current L6 Calibrator. Method Sheet Imprecision estimates were collected and computed following NCCLS document EP5-T2: Evaluation of Precision Performance of Clinical Chemistry Devices - Second Edition; Tentative Guideline.2 Precision estimates using the 2500 ng/mL L6 calibrator were generated over 5 days (instead of 20) using four replicates per day, instead of two.
| Proposed L6 Calibrator @ 2500 ng/mL | Current method Sheet | |||||||
|---|---|---|---|---|---|---|---|---|
| Pool-1 | Control 1 | Control 2 | Pool-2 | Control 3 | Control 1 | Control 2 | Control 3 | |
| mean = | 25.2 | 28.8 | 104.6 | 206.7 | 237.4 | 21.1 | 148.1 | 344.2 |
| Within SD = | 0.5 | 0.5 | 0.5 | 8.6 | 6.0 | 0.2 | 3.2 | 8.5 |
| Within %CV = | 1.9 | 1.8 | 0.5 | 4.1 | 2.5 | 1.0 | 2.1 | 2.5 |
| Total SD = | 0.6 | 0.6 | 1.4 | 8.6 | 6.0 | 1.5 | 7.4 | 17.1 |
| Total %CV = | 2.6 | 2.2 | 1.3 | 4.1 | 2.5 | 7.1 | 5.0 | 5.0 |
Table 2. Precision Observed for Bayer TEST point Controls and Human Serum Pools for Current and Proposed Calibrator Sets: Bayer Immuno 1 Ferritin Assay
Image /page/5/Figure/7 description: This image is a graph that shows the relationship between concentration Ferritin (ng/mL) and %CV. The x-axis represents the concentration of Ferritin in ng/mL, ranging from 0 to 250. The y-axis represents the %CV, ranging from 0.0 to 5.0. The graph includes two lines representing "Total %CV" and "Within %CV", as well as a dotted line indicating extrapolated %CV estimates to the left of the line.
Image /page/5/Figure/8 description: This image is titled "Figure 2 Graph of Within and Total-Run %CV for Bayer Immuno 1 Ferritin Assay." The image contains a title describing the contents of a graph. The graph is related to the Bayer Immuno 1 Ferritin Assay. The graph shows the Within and Total-Run %CV.
Bayer Immuno 1™ Ferritin 510(k) Application
{6}------------------------------------------------
7.0. . . . . . . . . ··············································································································································································
An estimate of analytical sensitivity (minimal detectable concentration) of the method was determined using Level 1 data generated as part of a performance study comparing multiple systems. reagents and calibrator sets. Analytical Sensitivity is a multi-system estimate of two times the within-run standard deviation of the zero calibrator. This value was determined to be 0.3 ng/mL, unchanged from our current expected value.
·············································································································································································· 8.0. . . . . .
A total of 102 samples were obtained from outside sources including samples with values greater than the current method's highest calibrator at 1000 ng/mL. Each sample was assayed in singlet using the current Bayer Immuno 1 Ferritin Assay (L6 = 1000 ng/mL) and compared to single results generated using the new extended range Ferritin (L6 = 2500 ng/mL). Three regression analysis plots were generated. The first (n = 72) assesses recoveries of all samples at concentrations less than 1000 ng/mL and will be added to the two comparisons in the current Method Sheet. The second (n = 30) assesses samples greater than 1000 ng/mL, but less than 2500 ng/mL and tests the samples diluted 1:5 in Level 1 calibrator for the current method and neat (undiluted) using the proposed L6 Calibrator method. The third comparison (Figure 5) includes all 102 data points.
Image /page/6/Figure/4 description: The figure is a scatter plot comparing two different methods of measuring Immuno 1 Ferritin. The x-axis represents the current method, and the y-axis represents the proposed method, both measured in ng/mL. A line of best fit is plotted with the equation y = 1.049x - 2.577, and the correlation coefficient r = 0.999, Sy.x = 6.94, n = 72, and the range is 30.2 - 966.7. The text "All samples assayed 'neat'" is at the bottom of the figure.
Image /page/6/Figure/5 description: The image is a title for a figure. The title reads "Figure 3. Bayer Immuno 1 Ferritin Assays: Methods Comparison Data (undiluted samples)." The title indicates that the figure will be comparing different methods of ferritin assays. The figure is from Bayer Immuno 1.
{7}------------------------------------------------
Image /page/7/Figure/0 description: This figure is a scatter plot comparing proposed Immuno 1 Ferritin to current Immuno 1 Ferritin. The x-axis represents current Immuno 1 Ferritin in ng/mL, while the y-axis represents proposed Immuno 1 Ferritin in ng/mL. The data points are scattered around a regression line, with the equation y = 0.975x + 291.1, a correlation coefficient of r = 0.931, Sy.x = 162.2, n = 30, and a range of 812-2412. The current samples were diluted 1:5.
Image /page/7/Figure/1 description: This figure is a scatter plot comparing two different methods of measuring Immuno 1 Ferritin levels. The x-axis represents the current method, while the y-axis represents the proposed method, both measured in ng/mL. The plot includes a regression line with the equation y = 1.162x - 9.21, a correlation coefficient of r = 0.990, Sy.x = 101.7, and n = 102, with a range of 30.2-2412. Open circles represent samples assayed neat, while closed circles represent samples diluted 1:5.
- Figure 4. Bayer Immuno 1 Ferritin Assays: Methods Comparison Data (samples >1000 ng/mL diluted for current method).
Figure 5. Bayer Immuno 1 Ferritin Assays: Methods Comparison Data (samples >1000 ng/mL diluted for current method).
. . . SPECIFICITY 9.0. . .
Interfering Substances
No reformulations were made to Reagents and the proposed new Level 6 calibrator will not impact specificity. No change will be made to the method sheet.
Cross Reactivity
No reformulations were made to Reagents and the proposed new Level 6 calibrator will not impact cross-reactivity. No change will be made to the method sheet.
{8}------------------------------------------------
No reformulations were made to Reagents and the proposed new Level 6 Calibrator will not impact dilution of high samples. No changes will be made to the method sheet.
This was confirmed by dilution of six samples with concentrations greater than the upper limit of the new analytical range (> 2500 ng/mL). Each sample was diluted 1:10 (1 part sample to 9 parts Bayer Immuno 1 Ferritin Level 1 Calibrator) and tested using both the Current and the Proposed calibration curves.
Results were compared two ways. First a t-test (paired two sample for means) determined no statistical difference between recoveries by the two calibration curves.
Then, a regression analysis between the samples confirmed that the diluted recoveries were equivalent (r ≥ 0.975, slope ≥ 0.975).
- Table 3 T-Test comparing the Results Generated from Six Diluted Patient Samples. The t-Stat is less than the t Critical meaning we cannot say the two populations are different.
| t-Test: Paired Two Sample for Means | ||
|---|---|---|
| L6 = 1000 | L6 = 2500 | |
| Mean | 6074.9 | 6203.7 |
| Variance | 9600749 | 9454447 |
| Observations | 6 | 6 |
| Pooled Variance | 0.998274 | |
| Hypothesized Mean Difference | 0 | |
| df | 5 | |
| t Stat | -1.725 | |
| t Critical one-tail | 2.015 | |
| t Critical two-tail | 2.571 | |
| t Stat is < t Critical: Do Not Reject Null Hypothesis |
Image /page/8/Figure/7 description: This figure is a scatter plot comparing proposed Immuno 1 Ferritin levels to current Immuno 1 Ferritin levels, both measured in ng/mL. The plot shows a linear relationship with the equation y = 0.991x + 185.7 and a correlation coefficient of r = 0.998. The standard error Sy.x is 201.9, with n = 6 samples, and the range of values spans from 2589 to 10108. The note indicates that all samples were diluted 1:10 in L1 and labeled as Calibrator.
Figure 6. Regression Analysis of Six Diluted Samples using the Current (L6 = 1000 ng/mL) Calibration Curve and the Proposed (L6 = 2500 ng/mL) Calibration Curve.
.. DETERMINATION OF REFERENCE INTERVALS 11.0 . . .
The change to a higher Level 6 calibrator does not impact sample recoveries, so no new claim is being made.
{9}------------------------------------------------
Image /page/9/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" around the perimeter. In the center of the logo is an abstract symbol that resembles an eagle or other bird.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
OCT 22 1998
Mr. Gabriel J. Muraca, Jr. Manager Requlatory Affairs Baver Corporation 511 Benedict Avenue Tarrytown, New York 10591
K982714 Re: Trade Name: Bayer Immuno 1™ System Ferritin Assay Regulatory Class: II Product Code: DBF Dated: July 29, 1998 Received: August 4, 1998
Dear Mr. Muraca:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in requlatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
{10}------------------------------------------------
Page 2
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling requlation (21 CFR Part 801 and additionally 809.10 for in_vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Autman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radioloqical Health
Enclosure
{11}------------------------------------------------
Attachment 6
Page 1 of 1
510(k) Number (if known): K983714
Bayer Immuno 1™ System Device Name: Ferritin Assay
Indications For Use:
This in vitro diagnostic method is intended to quantitatively measure ferritin (an iron-storage protein) in human serum on the Bayer Immuno 1 System. Measurements of ferritin aid in the diagnosis of diseases affecting iron metabolism, such as hemochromatosis (iron overload) and iron deficiency anemia.
This diagnostic method is not intended for use on any other system.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH Office of Device Evaluation (ODE)
Mak
(Division Sign-Off)
Division of Clinical Laboratory Devices K982714
510(k) Number
Prescription Use
OR
Over-The-Counter Use
(Per 21 CFR 801.109)
Optional Format 1-2-96
§ 866.5340 Ferritin immunological test system.
(a)
Identification. A ferritin immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the ferritin (an iron-storing protein) in serum and other body fluids. Measurements of ferritin aid in the diagnosis of diseases affecting iron metabolism, such as hemochromatosis (iron overload) and iron deficiency amemia.(b)
Classification. Class II (performance standards).